Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Zura Bio LimitedNASDAQ: ZURA
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 43.3% from a year ago
Total equity stood at $216.9M at the end of Q1 FY2026, up 43.3% from a year earlier and up 113.6% from the prior quarter.
Context
- Total equity amounted to 94.9% of total assets at the end of Q1 FY2026, up 7.1 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +43.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 101.54M USD
- Year-over-year change
- -36.5%
- 4-year CAGR
- -6.0%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 101.54M | -36.5% |
| FY2024 | 2024-12-31 | 160.02M | +101.2% |
| FY2023 | 2023-12-31 | 79.55M | +460.7% |
| FY2022 | 2022-12-31 | (22.06M) | -116.9% |
| FY2021 | 2022-03-31 | 130.2M | — |
Total Equity vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 total equity of $216.9M is the 2nd highest of the 11 companies compared; the peer median is $111.39M.
- Its year-over-year change of +43.3% is the 3rd highest of 11, against a peer median of -21.0%.
- Total equity amounts to 94.9% of total assets for ZURA, versus a peer median of 79.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $206.52B | +493455.8% | +25.8% | 96.1% | |
ZURAZura Bio Limited | Mar 2026 | $216.9M | +43.3% | — | 94.9% |
| Mar 2026 | $198.61M | +632.0% | +35.7% | 84.3% | |
| Mar 2026 | $191.36M | -18.1% | -7.5% | 78.0% | |
| Mar 2026 | $144.42M | -25.7% | -20.7% | 81.2% | |
| Mar 2026 | $116.59M | +24.6% | -41.4% | 37.0% | |
| Mar 2026 | $106.19M | -11.1% | -20.3% | 78.6% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $102.46M | -26.3% | — | 95.1% |
| Mar 2026 | $86.99M | -42.3% | — | 88.2% | |
| Mar 2026 | $31.27M | -69.7% | -30.8% | 48.6% | |
| Mar 2026 | -$76.41M | -23.9% | — | 34.4% | |
| Peer median (excluding ZURA) | $111.39M | -21.0% | -20.3% | 79.9% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.